Incyte Corp.
INCY evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for INCY—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · INCY
Incyte Corp. is a biopharmaceutical company focused on transitioning from a single cornerstone product (Jakafi) to a diversified portfolio in hematology, oncology, and immunology, with a strong financial position and multiple late-stage clinical catalysts.
Key risk: Dependence on Jakafi revenue
BioSniper Score
Based on 6 of 6 signals
Market Cap
$25.21B
Cash Runway
—
Lead Asset
niktimvo (Approved)
Next Catalyst
Phase3_Topline · Dec 26, 2026Financial data as of Mar 31, 2026.
Tracking 4 pipeline candidates · 168 clinical trials · 20 catalysts · 6 FDA decisions for Incyte Corp..
Incyte Corp. is a biopharmaceutical company focused on transitioning from a single cornerstone product (Jakafi) to a diversified portfolio in hematology, oncology, and immunology, with a strong financial position and multiple late-stage clinical catalysts.
- Cash and equivalents of $3,462.9M as of 2026-03-31 [sec].
- Total revenue of $1,272.7M and net income of $303.3M for the period ending 2026-03-31 [sec].
- Shareholders' equity of $5,167.5M and total debt of $29.4M as of 2026-03-31 [sec].
- Core business outside Jakafi grew 53% in net sales from $826.8M in 2024 to $1.26B in 2025, driven by Opzelura, Monjuvi/Minjuvi, Zynyz, and Niktimvo [sec · filed 2026-04-28].
- By end of 2026, the company expects to have 14 pivotal trials underway supporting its portfolio [sec · filed 2026-04-28].
What works
- Strong financial position with $3.46B in cash and minimal debt of $29.4M as of 2026-03-31 [sec].
- Diversifying revenue base: Core business outside Jakafi grew 53% in 2025, with Opzelura contributing $678M in net sales (up 33% year-over-year) [sec · filed 2026-04-28].
- Rich late-stage pipeline with multiple Phase 3 topline readouts expected through 2027 for povorcitinib, ruxolitinib, and other assets [catalyst_timeline].
- Management expects to have 14 pivotal trials underway by end of 2026, indicating strong R&D momentum [sec · filed 2026-04-28].
What to weigh
- The company remains heavily reliant on Jakafi (ruxolitinib) for a significant portion of revenue, though the core business outside Jakafi is growing [sec · filed 2026-04-28].
- Some clinical development goals were not achieved in 2025, including the submission of an sNDA for ruxolitinib cream for prurigo nodularis [sec · filed 2026-04-28].
- Forward-looking statements caution about risks including market competition, pricing regulation, and reimbursement limitations [sec · filed 2025-04-29].
From the filings
Quoted directly from source documents.
Growth of core business outside Jakafi
“The Core Business outside of Jakafi demonstrated robust momentum, growing from $826.8 million in 2024 to $1.26 billion in 2025, representing a 53% increase in net sales.”
SEC filings · April 28, 2026
Pipeline expansion and pivotal trials
“By the end of 2026, we expect to have 14 pivotal trials underway supporting our portfolio.”
SEC filings · April 28, 2026
Missed clinical development goal in 2025
“During 2025, we did not achieve our goal of submitting a Supplemental New Drug Application ("sNDA") for ruxolitinib cream for PN.”
SEC filings · April 28, 2026
Catalyst timeline
- 2026-12-26 · Phase3_Topline — Phase 3, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib — Topline data for povorcitinib in a long-term safety and efficacy study; results will inform the drug's profile in chronic inflammatory conditions.
- 2027-02-24 · Phase3_Topline · povorcitinib — Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib — Topline data for povorcitinib in a 52-week placebo-controlled study; key for registration in prurigo nodularis or similar indications.
- 2027-03-13 · Phase3_Topline · ruxolitinib — Phase 3, Randomized, Double-Blind, Safety, and Efficacy Study of Ruxolitinib Cream in Pediatric Patients — Topline data for ruxolitinib cream in pediatric atopic dermatitis; potential label expansion for Opzelura.
- 2027-03-16 · Phase3_Topline · povorcitinib — Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib — Another Phase 3 topline for povorcitinib; may cover additional indications or confirm earlier results.
- 2027-03-30 · Phase3_Topline — Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics — Topline data from an open-label study; likely for a pipeline asset in hematology or oncology.
- 2027-04-01 · Phase3_Topline — Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Tafasitamab — Topline data for tafasitamab in a single-arm study; could support label expansion in lymphoma.
- 2027-05-03 · Phase3_Topline · povorcitinib — Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib — Topline data for povorcitinib in a placebo-controlled study; further defines its efficacy in inflammatory diseases.
- 2027-07-11 · Phase3_Topline · ruxolitinib — Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream — Topline data for ruxolitinib cream in a vehicle-controlled study; potential for new dermatological indications.
Risks & what to watch (3)›
Key risks
- Dependence on Jakafi revenue — Despite diversification, Jakafi remains a cornerstone product; any decline in its sales could materially impact revenue [sec · filed 2026-04-28].
- Clinical trial execution risk — Missed 2025 goal for ruxolitinib cream sNDA submission highlights risk of delays in regulatory milestones [sec · filed 2026-04-28].
- Market and pricing pressures — Forward-looking statements cite risks from market competition, price regulation, and reimbursement limitations [sec · filed 2025-04-29].
What to watch
- Phase 3 topline results for povorcitinib in hidradenitis suppurativa (HS) expected December 2026 [catalyst_timeline].
- Phase 3 topline results for ruxolitinib cream in pediatric atopic dermatitis expected March 2027 [catalyst_timeline].
- Phase 3 topline results for povorcitinib in prurigo nodularis (PN) expected February 2027 [catalyst_timeline].
- Progress toward 14 pivotal trials by end of 2026 as a measure of pipeline execution [sec · filed 2026-04-28].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Incyte Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Incyte Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 0.31 · 4% dilution
Lead: Approved
4 candidates
20 upcoming, next in ~118d
0 buys · 25 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
810
Total value held
$18.98B
| Holder | Shares | Value |
|---|---|---|
| baker bros. advisors lp | 30,744,412 | $2.89B |
| vanguard capital management llc | 21,860,132 | $2.06B |
| blackrock, inc. | 18,978,198 | $1.79B |
| dodge & cox | 12,252,356 | $1.15B |
| state street corp | 9,641,384 | $907.4M |
| vanguard portfolio management llc | 7,759,183 | $730.3M |
| aqr capital management llc | 5,807,930 | $536.1M |
| geode capital management, llc | 4,703,184 | $441.1M |
| renaissance technologies llc | 3,651,532 | $343.7M |
| wellington management group llp | 3,266,136 | $307.4M |
Showing top 10 of 810 institutional holders of Incyte Corp.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 9.8%
- Days to cover
- 7.8
- Shares short
- 11,358,353
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
INCY short interestGovernance
Frequently asked questions
What is the AI investment thesis for Incyte Corp.?
Incyte Corp. is a biopharmaceutical company focused on transitioning from a single cornerstone product (Jakafi) to a diversified portfolio in hematology, oncology, and immunology, with a strong financial position and multiple late-stage clinical catalysts.
What is Incyte Corp.'s lead drug candidate?
Incyte Corp.'s most advanced tracked candidate is niktimvo (Approved).
What is Incyte Corp.'s next catalyst?
Incyte Corp.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Parti" — expected December 26, 2026.
Who is the CEO of Incyte Corp.?
Mr. William J. Meury is the chief executive officer of Incyte Corp. (INCY).
Where is Incyte Corp. headquartered?
Incyte Corp. (INCY) is headquartered in Wilmington, DE, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.